For over 10 years, Selexis has built interactive collaborations, partnerships and commercial deals with leading biotechnology and pharmaceutical companies worldwide. Our innovative technologies and world-class expert services significantly reduce the time, effort, and costs associated with developing high-performance mammalian cell lines for therapeutic protein production (e.g. MAbs, growth factors, enzymes). From discovery to Phase II clinical trials, Selexis’ technology has been and is currently being used by more than 100 companies worldwide. Furthermore, the recent launch of the Selexis SUREvariant screening™ platform enables our customers to improve clinical success by identifying high quality lead candidates.
The development of the Selexis SUREtechnology Platform™ means it is now possible to generate stable and high performing manufacturing cell lines in approximately 3 months with productivity levels around 2-5 g/L; thereby expediting entry into CMO manufacturing while reducing the need for larger bioreactor capacity.
